Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies targeting FcRn to treat autoimmune diseases. Its lead candidate, IMVT-1402, aims to reduce pathogenic IgG antibodies across multiple indications, including Graves' disease, myasthenia gravis, CIDP, and various dermatologic and rheumatologic conditions. The company focuses on innovative, targeted therapies with potential best-in-class efficacy, safety, and convenient self-administration for autoimmune patient populations worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.